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Abstract
Purpose: To evaluate the use of high-dose radiotherapy using carbon ions (C12) on non-adenoid cystic malignant
salivary gland tumors (MSGT).
Patients and methods: Between 2009 and 2013, patients with biopsy-proven non-ACC MSGT histologies of the
head and neck received a combined regimen of IMRT plus C12 boost. Treatment toxicity (CTC v3), response
(RECIST 1.1), control and survival rates were retrospectively analyzed.
Results: 40 patients with pathologically confirmed non-ACC MSGT (T4: 45 %; N+: 40 %; gross residual: 58 %;
mucoepidermoid carcinoma (MEC): 45 %; adenocarcinoma: 20 %) were treated with a median of 74 GyE (80 Gy
BED). Chemoradiation was given in 5 patients with MEC. Grade III acute toxicity was observed in up to 15 %
(mucositis, dermatitis, dysphagia), no higher-grade late toxicity occurred to date. At a follow-up of 25.5 months,
LC, and PFS at 2 and 3 years are 81.5 % (LC) and 66.8 % (PFS), OS at 2 and 3 years is 83.6 % and 72.8 %. Most
frequent site of disease progression was distant metastasis. Histologic subtype correlated with LC and PFS.
Resection status (gross vs microscopic disease) had no significant effect on LC, PFS, or OS.
Conclusion: The treatment is well tolerated, no higher grade late effects were observed. Considering the
negative pre-selection, LC, PFS and OS are promising. While histology and site of origin significantly influenced
control and survival rates, resection status did not, potentially due to the effect of dose escalation.
Background
Malignant salivary gland tumors (MSGTs) are a
heterogenous group of malignancies with more than 20
histological subtypes of different biological and clinical
behavior [1].
While adenoid cystic carcinomas (ACC) generally
show a very indolent course of disease despite frequent
distant metastases [2], this is not the case for other
high-grade MSGTs. These may exhibit aggressive local
growth patterns as well as early distant disease [3].
Retrospective analyses of larger patient cohorts could
establish the use of postoperative radiotherapy and dose-
dependence of locoregional control in MSGTs [4–7].
Particle therapy as either neutron or carbon ion therapy
has been evaluated in MSGT with promising control
rates [8–10]. However, most of these series include a sig-
nificant proportion of patients with ACC whose natural
history of disease and biological behavior is distinctly dif-
ferent from non-ACC histologies. We therefore present
our experience with a combined regimen of IMRT plus
carbon ion boost in the treatment of non-ACC MSGTs of
the head and neck.
Patients and methods
Immobilization, target volume definition, and treatment
planning
Patients were immobilized with custom-made thermo-
plastic head masks including shoulder fixation (Head-
Step®). Target delineation was based on contrast-enhanced
CT and MRI scans. Two target volumes were outlined:
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CTV1 included the macroscopic tumor and tumor bed,
the extended target volume (CTV2) included the CTV1
and typical pathways of spread as well as ispilateral nodal
levels (II and III). If the primary tumor was located at or
crossing midline, bilateral nodes were included. A 3 mm
margin was added to the CTVs to generate PTVs. The
PTV margin was reduced at sites were it would extend
into critical structures (i.e. optic pathways), no margin was
added to organs at risk.
C12 plans were created using Siemens TPS© which in-
corporates biological plan optimization according to the
local effect model (LEM) [11] to account for increased
biological effectiveness. Hypofractionation effects are not
included in this model; doses need to be converted ac-
cording to the standard LQ model to yield Gy BED.
IMRT plans were generated either using MRC KonRad©
on the Siemens Syngo© platform or tomotherapy©.
Dose prescription and organs at risk
Both C12 and photon doses were prescribed to the
median PTV, which is covered by the 95 % prescription
isodose. Normal tissue constraints according to Emami et
al. [12] were adhered to. Doses were reduced beyond the-
ses values to as low as reasonably achievable without com-
promising PTV coverage. Mean dose to at least one
parotid gland was kept below 26 Gy.
Patients received a sequential C12 boost in 3 GyE per
fraction followed by normofractionated photon IMRT.
Most patients received IMRT plus up-front C12 boost
(median C12 dose: 23.95 GyE, median IMRT dose:
50 Gy). Two patients underwent C12 only to a total dose
of 66 GyE.
Treatment
C12 treatment was applied using intensity-controlled
raster-scanned technique (active beam application) [13]
using one to five non-coplanar treatment beams under
daily image guidance with orthogonal x-rays and 6 degrees
of freedom (DOF) position correction [14]. C12 treatment
was routinely available at the Heidelberg Ion Beam Ther-
apy Centre (HIT) in 5 to 6 fractions per week.
IMRT treatments were carried out in step and shoot
technique using a 6 MV linear accelerator or tomother-
apy unit under regular image guidance with MV cone-
beam CT.
Staging and follow-up
Initial staging included full clinical examination with
panendoscopy, local imaging (contrast-enhanced CT/
MRI), and chest CT. Patients were followed up 6-8
weeks post completion of treatment, 3 months thereafter
and then in 6 monthly intervals with MRI of the head
and neck. Yearly chest CTs were recommended to exclude
distant disease. In addition, patients were encouraged to
regular visits at their referring surgeon incl. full ENT
examinations.
Evaluation
Medical records of all patients treated for pathologically
confirmed MSGT between 2009 and 2013 were retrieved
and analyzed. Acute and late toxicities were scored ac-
cording to CTCAE v.3. Tumor staging was performed
on initial diagnostic scans to the most recent TNM clas-
sification [15], response assessment on follow-up MRI
scans according to RECIST 1.1 [16]. Both were carried
out by this institution’s MSGT experts.
Time to event data was calculated from radiotherapy
treatment start to last follow-up or death according to
the Kaplan-Meier method. Loco-regional control (LC)
was defined as the absence of further tumor growth fol-
lowing radiotherapy or the absence of further tumor
growth following best response of the treated lesion(s).
Progression-free survival (PFS) was defined as the ab-
sence of locoregional or distant failure or death of any
cause. Kaplan-Meier curves were compared using log-
rank tests; statistic analyses were performed with the
Addinsoft© xlstat life package 2015.
All patients gave written informed consent prior to
initiation of treatment, the analysis is in accordance with
the current declaration of Helsinki and approved by the
institutional review board.
Ethics and approval
The study was reviewed and approved by the local
institutional review board (S-141/2014). The analysis is in
accordance with the current declaration of Helsinki.
Results
Between 11/2009 and 05/2013, 291 patients with MSGTs
received carbon ions as part of their primary treatment.
40 patients had pathologically confirmed MSGT other
than ACC. Median age was 60 years [range: 35-80 a]. 31
patients underwent surgery prior to radiotherapy, 23
patients had gross residual/inoperable (58 %) and 17
patients had microscopic residual (43 %) disease at
RT treatment planning. 7 patients received treatment
for locally recurrent MSGT but had not undergone
prior radiotherapy. Most common histology was
mucoepidermoid carcinoma in 18 patients (45 %) and
adenocarcinoma in 8 patients (20 %). Most common
sites of origin were parotid gland (50 %) and subman-
dibular gland (13 %). 18 patients (45 %) had T4 stage
tumors, 16 patients (40 %) showed nodal metastases.
38 patients received combined radiotherapy with IMRT
plus up-front C12 boost to a median dose of 23.95 GyE
C12 and 50 Gy IMRT corresponding to a median total
dose of 74 GyE and approximately 80 Gy BED. Two
patients underwent C12 only to a total dose of 66 GyE for
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very small primary tumors. With a median CTV1 (C12) of
120 ml and CTV2 (IMRT) of 424 ml, treatment volumes
were comparatively extensive (Table 1: patient baseline
characteristics).
Five patients with mucoepidermoid carcinoma re-
ceived combined chemoradiation with cisplatin 40 mg/m
sq weekly following interdisciplinary discussion of these
specific cases.




histology mucoepidermoid carcinoma 18 45
adeno carcinoma 8 20
acinic cell carcinoma 3 8
squamous cell carcinoma 2 5
salivary duct carcinoma 2 5
NOS 2 5
basal cell-adeno carcinoma 2 5
adenosquamous carcinoma 1 3
myoepithelial carcinoma 1 3
basaloid carcinoma 1 3
stage T 1 3 8
T 2 5 13
T 3 13 33
T 4a 10 25
T 4b 7 18




treatment for recurrent disease 7 18
site parotid gland 20 50




lacrimal gland 2 5
paranasal sinus 2 5
petrous bone 2 5
middle ear 1 3
nasopharynx 1 3
age median in years [range] 60 35-80
follow-up all, median in months [range] 25.5 2.5-58.4
alive, median in months [range] 27.3 3-58.4
target volume CTV1 (boost) in ml 120 34-564
CTV2 (extended target volume) in ml 424 105-1538
dose C12 in GyE [range] 23.95 17.4-24.4 2 pts: C12 only with 66 GyE
IMRT in Gy [range] 50 42-56.4
total in GyE [range] 74 50.4-74.8
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Follow-up is 25.5 months [range: 2.5-58.4 months] and
27.3 months [range: 3-58.4 months] for patients alive. 8
patients have deceased due to disease progression.
As expected, mucositis and dermatitis were the most
prevalent acute radiation effects. Despite 5 patients
undergoing combined chemoradiation, higher-grade mu-
cositis was observed in only 15 % (6 patients). 18 (45 %)
patients developed weight loss, however, only 20 % of
patients reported dysphagia grade II or III. Trismus was
present in 3 patients, in all of those following initial
surgery. The most commonly reported late effect was
xerostomia grade I (30 %), no higher grade late effects
were observed to date. 5 patients developed hearing
impairment (13 %) and sensory impairment (13 %), 3
patients rhinitis sicca symptoms (8 %). One patient
developed tissue necrosis in the nasopharynx follow-
ing combined chemoradiation for mucoepidermiod
carcinoma of the nasopharynx. Fortunately, this did not
result in any late sequelae or cranial nerve impairment
(Additional file 1: Table S2: treatment toxicity).
According to RECIST, 3 patients (8 %) developed
complete remissions (CR) 6 weeks post completion of
radiotherapy, 10 patients (25 %) partial remissions (PR),
9 patients (23 %) remained stable (SD). In the 16
patients with microscopic residual disease, and in 2
patients deceased prior to first follow-up, response
according to RECIST was not assessable. Best re-
sponse was CR in 7 patients (18 %), PR in 11 patients
(28 %), and SD in 4 patients (10 %). Figure 1 shows
the dose distribution of C12 plan (24 GyE) for a pa-
tient with mucoepidermoid carcinoma of the parana-
sal sinus, Fig. 2a and b show the initial MRI scan for
treatment planning and Fig. 3a and b observed treat-
ment response with a very good partial remission
6 weeks post completion of RT.
LC, and PFS at 2 and 3 years are 81.5 % (LC) and
66.8 % (PFS), OS at 2 and 3 years is 83.6 % and 72.8 %
(Fig. 4).
7 patients developed locoregionally recurrent disease:
3 patients in field, 2 patients at the field edge/gradient
where the optic nerve was spared, and 2 patients devel-
oped nodal recurrences. 11 patients showed distant dis-
ease progression, most commonly as bony (7 pts) and
lung (5 pts) metastases, less frequently as soft tissue (2
pts), skin (2 pts), and liver (1 pt) metastases. Further
treatment included palliative chemotherapy (6 pts), pal-
liative RT of bone metastases (5 pts), re-irradiation (3
pts), and salvage surgery (1 pt).
On univariate analysis, LC correlated significantly with
histological subtype (p < 0.001). Figure 5 shows LC ac-
cording to the most common histologies with MEC
yielding the least favorable LC. Histology did influence
PFS (p = 0.004) (Additional file 2: Figure S1) and distant
control (p = 0.003), however, no influence on OS could
be detected. Acinic cell carcinoma had the most and
adenocarcinoma the least favorable outcome regarding
PFS and distant control. While site of origin did not
correlate with LC (p = 0.237), it did influence PFS (p =
0.021) (Additional file 3: Figure S2), distant control (p =
0.053), and OS (p = 0.010) with submandibular gland as
the least favorable site (Additional file 4: Figure S3).
Resection status had no demonstrable effect on PFS,
distant control, or OS. Patients with gross residual
disease tended to have lower LC, however, this was
not statistically significant in this analysis.
Discussion
While dose escalation using high-LET radiotherapy is
seen as beneficial in the treatment of MSGTs and
Fig. 1 C12 treatment plan of a patient with mucoepidermoid carcinoma of the paranasal sinus undergoing combined IMRT plus C12 boost. C12
plan based on 2 beams, intensity-controlled C12 therapy (ICCT) to 24 GyE in 3 GyE per fraction. a and b: axial; c: coronal distribution
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especially ACC of the head and neck [9, 17], the situ-
ation is less clear for non-ACC MSGT histologies.
In contrast to ACC, many high-grade non-ACC histolo-
gies such as mucoepidermoid carcinoma and adenocarcin-
oma are characterized by a very aggressive course of
disease, frequent nodal and early distant metastases [2, 3].
Adjuvant radiotherapy at doses exceeding 60 Gy is
recommended in patients with risk factors such as
advanced T-stage, nodal metastases, perineural spread,
involved margins, or high-grade histology [2–6].
In our cohort, all patients had at least one of these risk
factors: all patients had involved margins and more than
50 % gross residual disease, most patients had advanced
tumor stages and 40 % cervical nodal metastases, hence
representing a very unfavorable pre-selection [4, 8, 18–21]
underrepresented in most other series.
Often, outcome is reported for all MSGTs [5, 7–9] and
rarely according to histology [2].
MEC and AC were the most common histologic sub-
types in our cohort, also representing two MSGT histolo-
gies with the highest potential systemic activity [2, 20–22].
Indeed, most common site of relapse were distant metas-
tases (28 %) which supports findings of Loh, Salgado,
Chung and Garden [6, 22–24]. Information on LC in this
specific, subset of patients with advanced tumor stages,
residual disease and unfavorable histology is rare:
In a large analysis of 207 patients with MSGTs of the
major salivary glands treated between 1960 and 2004 at
the MD Anderson Cancer Center, LC in node positive
patients, advanced T-stages, positive margin or high-
grade histology is between 60 and 70 % at 5 years [6].
The MSKCC experience of 98 patients with MSGT of
the minor salivary glands treated between 1990 and
2010 yields LC rates of around 80 % at 5 years and sig-
nificantly inferior results for MECs and adenocarcinoma
[22]. LC at 3 years was around 80 % in 54 patients
Fig. 2 Initial, contrast-enhanced T1-weighted and fat-saturated MRI scan of the patient with mucoepidermoid carcinoma of the paranasal sinus prior
to initiation of radiotherapy (a: axial; b: coronal)
Fig. 3 Follow-up contrast-enhanced T1-weighted and fat-saturated MRI scan of the patient with mucoepidermoid carcinoma of the paranasal
sinus 6 weeks post completion of radiotherapy (a: axial; b: coronal)
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Fig. 4 Locoregional control (LC), progression-free survival (PFS), overall survival (OS)
Fig. 5 LC according to histologic subtype. AC: adenocarcinoma; ACI: acinic cell carcinoma; MEC: mucoepidermoid carcinoma. Note only the most
frequent subtypes are shown to improve visibility
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treated with postoperative radiotherapy in the Standford
series where advanced T-stage, nodal involvement, and
MEC histology was associated with worse outcome [21].
In view of these tumors’ relative radioresistance, neutron
radiotherapy has been employed in order to improve con-
trol rates. Already in the late 1980s, Griffin and Laramore
could show superior LC rates for neutron radiotherapy
in the randomized MRC trial albeit with low patient
numbers (32 pts) and considerable late toxicity [9, 25].
Stannard et al published their experience in the largest
cohort of patients treated with neutrons for MSGTs so
far. They found LC rates between 35 % and 50 % for
patients with T4 or large tumors, high-grade histology,
and nodal metastases [8]. A LC of 72 % at 3 years was
reported by Tsuji et al from the NIRS carbon ion center
in 26 patients with advanced adenocarcinoma of the
head and neck [10].
Despite negative prognostic factors in all our patients,
our experience with LC rates of more than 80 % at 2
and 3 years therefore compares favorably with previously
published experience.
Inferior results regarding LC and PFS for MEC and
adenocarcinoma in our series is supported by other ob-
servations and not unexpected [2, 4, 20–22].
Site of origin did influence PFS and OS in our cohort
on univariate analysis as reported by other investigators
[2, 4, 21, 26]. However, in contrast to all other previously
published experience [2, 4, 5, 7, 21], resection status
(gross residual tumors vs microscopically involved mar-
gins) had no significant influence on LC, which may be
an effect of dose escalation to approximately 80 Gy BED.
OS in this cohort is 72.8 % at 3 years and is in line
with experience in larger series [7, 8, 24, 27] and the
SEER based analysis [20]. It is slightly lower than in the
cohort published by Garden [6] which may be due to the
high percentage of ACC patients in their series.
As expected, mucositis and dermatitis were the most
prevalent acute radiation effects. Despite 5 patients
undergoing combined chemoradiation, higher-grade mu-
cositis was observed in only 15 % (6 patients).
No high-grade late toxicity was observed in this cohort
so far. Observed toxicity such as hearing impairment
and sicca symptoms correlate well with site and extent
of treatment field. As described, one patient developed
normal tissue necrosis in the high dose area in the naso-
pharynx following combined chemoradiation. Unfortu-
nately, she still developed an in-field recurrence but
does not show any further late toxicity or sequelae. In
their retrospective analysis of 98 patients with minor
salivary gland malignancies, Salgado et al describe acute
and late toxicities including several high-grade late
effects (dysphagia, xerostomia, hearing loss) but also 2 out
of 98 cases of radiotherapy necrosis, which corresponds to
the percentage observed in our cohort [22]. Ten percent
of patients developed higher-grade toxicities in the Florida
cohort published by Mendenhall et al [7]. The neu-
tron experience reports severe late toxicities in 9 % of
patients [8] and significantly higher than in compar-
able photon treatments [9]. Despite large treatment
fields and chemoradiation in 20 % of patients, treat-
ment with IMRT plus carbon ion boost was very well
tolerated. Higher-grade acute effects such as mucositis
and dysphagia were rare and rates corresponded well
to our previously published experience [28, 29]. No
temporal lobe changes were observed. In view of the
comparatively short follow-up of our patients (25 months),
further monitoring is warranted.
No report exists as to observed treatment response of
non-ACC of the head and neck so far. Early and best re-
sponse rates are in line with our previously published
experience in MSGT [29]. Still, 3 patients developed in-
field recurrences, 2 patients recurrences within the dose
gradient towards the optic system. While further dose
escalation should be approached with caution, recur-
rences within the gradient underline the necessity to
clearly discuss the issue of sparing specific structures
and its potential consequences with the patient.
Chemoradiation in MSGTs is still discussed contro-
versially. There is only limited data on the use of
concurrent platin-containing chemoradiation and pa-
tient numbers are small [30–34]. It is still unclear
whether the addition of chemotherapy to high-dose
irradiation does prevent early systemic metastases and
even less clear whether the addition of chemotherapy
to particle treatment has an added benefit. Once re-
cruitment of the RTOG 1008 trial is completed and
results are available [35], we may gain more insight
into these issues for photon radiotherapy. In particle
therapy however, we do believe these questions
should be addressed in a prospective clinical trial.
Conclusion
Overall acute and late treatment toxicity of the combin-
ation of IMRT plus C12 boost remains consistently low,
no higher grade late toxicities were observed. LC, PFS
and OS are promising, especially considering the nega-
tive preselection of patients with advanced disease and
gross residual tumors. While histology and site of origin
significantly influenced control and survival rates, resec-
tion status did not potentially due to the effect of dose
escalation, which therefore appears to be beneficial also
in non-ACC histologies.
Previous presentation
Intermediate results were presented as poster at DEGRO
meeting in Düsseldorf, in 2014.
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